Image Guided Surgery Devices Industry Outlook, Growth Prospects and Key Opportunities
The global image guided surgery devices market is likely to grow significantly during the forecast period, due to increasing prevalence of chronic diseases, and cancer, rising geriatric population and increasing cases of neurological disorders. In addition to these factors, rising healthcare expenditure and technological advancements in medical imaging also contributes to the growth of the overall market. High cost of imaging techniques and stringent regulatory requirements are some of the key factors restraining the global market growth.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market/report-sample
As per the findings of the research, the CT is the largest segment, based on device type, in the global image guided surgery devices market. CT is a non-invasive, accurate and fast diagnostic imaging test. It uses x-ray equipment to produce 3D images by taking series of images from different angles. Each image created during the CT procedure shows the bones, tissues and organs in a thin “slice” of the body.
It provides cross-sectional images generated during the CT scan and can be reformatted in multiple planes. It is used for diagnosing skeletal abnormalities, blood clots, blood vessel aneurysm and cancer. Neurology has been the largest application area for image guided surgery devices, followed by orthopedic surgery, ENT surgery, oncology surgery and others.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market
Some of the key players in the global image guided surgery devices market include Siemens AG, GE Healthcare, Koninklijke Philips N.V., Canon Inc., Hitachi, Ltd., KARL STORZ GmbH & Co. KG., Medtronic, Inc., St. Jude Medical, Inc., Varian Medical Systems, Inc., Smith & Nephew plc, Integra LifeSciences Corporation and Zimmer Holdings, Inc.
mTOR Inhibitors Market - Global Industry Analysis, Size, Growth and Demand, 2023
The global mammalian target of rapamycin inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.
Explore Report at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market
The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.
Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.
Europe is the second largest market for mTOR inhibitors. During the forecast period, the mTOR inhibitors market would witness highest growth in Asia-Pacific, attributed to increasing number of new entrants, improving healthcare infrastructure, increasing prevalence of chroic diseases and increasing healthcare expenditure.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market/report-sample
The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.
Ocular Pain Treatment Market - Pipeline Analysis, Share and Forecast to 2023
The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.
Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market
Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye. Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.
A large number of pharmaceutical companies are constantly working for the research and development of ocular pain treatment. However, certain factors such as high treatment cost, less awareness about the eye disease among population and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/report-sample
Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc., Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.
Personalized Medicine Market - Global Industry Analysis, Size, Growth and Demand, 2023
The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/report-sample
The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.
National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.
Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market
Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.
Cardiovascular Devices Market Trends, Size, Growth and Demand, 2023
Cardiovascular devices are used to treat cardiovascular diseases that include numerous problems, most of them related to atherosclerosis. Atherosclerosis is a medication state characterized by when a substance called plaque builds up in the walls of the arteries. It narrows the arteries, making it harder for blood to flow through and affects the normal supply of blood and causes heart attack. Heart attack occurs when the blood flow of the heart is blocked by a blood clot. Other cardiovascular diseases, such as ischemic stroke and heart failure, occur when a blood vessel is blocked by clot. In addition, heart failure, sometimes called congestive heart failure, means the heart isn't pumping blood properly. Arrhythmia is also one of the major cardiovascular diseases usually characterized by abnormal rhythm of the heart. To overcome these problems, various cardiovascular devices are used to diagnose and treat heart diseases.
For more information visit: https://www.psmarketresearch.com/market-analysis/cardiovascular-devices-market
The global cardiovascular devices is segmented into cardiac rhythm management, cardiovascular monitoring and diagnostic, interventional cardiology, prosthetic heart valves, external defibrillators, electrophysiology, peripheral vascular, cardiac assist and cardiovascular prosthetic and cardiovascular surgery. Cardiac rhythm management device is the largest segment in global cardiovascular devices market.
North America accounts for the largest cardiovascular devices market followed by Europe. This is due to increased awareness about various heart diseases, developed economies and increased overweight or obese people in the region. In addition, high disposable incomes and favorable reimbursement policies are also supporting the growth of cardiovascular devices market in the region. The U.S., followed by Canada, is the largest market for cardiovascular devices in North America. Germany, France and the U.K. are some of the largest markets for cardiovascular devices in the European region. However, Asia-Pacific represents the fastest growing region in the global cardiovascular devices market. This is due to increasing awareness about various heart diseases in the region and increasing number of aged people in the region.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cardiovascular-devices-market/report-sample
However, stringent regulations and legislations is a key restraint of the global cardiovascular devices market. In addition, high cost of cardiovascular devices and lack of skilled healthcare professionals to operate expensive devices also obstructs growth of cardiovascular devices. Rapid product launches and increasing mergers and acquisitions between cardiovascular devices manufacturing companies are key trends in global cardiovascular devices market.
Some of the major competitors in the market are Medtronic Inc., MAQUET GmbH & Co. KG, Sorin Group, Terumo Corporation, C. R. Bard Inc., SEMMT Inc., Cardima Inc. CyberHeart Incorporated, Kardium Inc., EndoPhotonix Inc., St. Jude Medical, MedWaves Incorporated and Edwards Lifesciences.
Acute Ischemic Stroke Diagnosis and Treatment Market Size, Forecast to 2023
Acute ischemic stroke refers to a sudden loss of certain brain function owing to uneven or lack of blood to the brain. Acute ischemic functions are mainly triggered by atherosclerosis plaques blocking blood vessels, blood clots locking the blood distribution to or from arteries nourishing the brain, or narrowing of blood vessels of the brain. Acute ischemic stroke is one of the major causes of permanent disability in the patients. It is also the third largest reason of death worldwide. Acute ischemic stroke can affect persons of all age groups. However, acute ischemic stroke most commonly affects the individuals, who are above 60 years, the risk of acute ischemic stroke increases with age. Driven by the technical advancement in diagnosis, the acute ischemic stroke diagnosis and treatment demand is expected to experience an escalating demand in coming years.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/acute-ischemic-stroke-diagnosis-and-treatment-market/report-sample
The advancements in the surgical devices technology, in addition with the rising occurrence of acute ischemia stroke cases among the patients are some of the dominant driving factor for the surgery in acute stroke treatment. Some of the other factors driving the market include, aging population mainly in the developed countries of Europe and North America. The development of the effective medication in the treatment of ischemic stroke is accepted to hinder the acceptance of expensive surgery in the ischemic stroke diagnosis market. The development of desmoteplase, a novel next-generation thrombolytic, is one of the major advancement of in the treatment technology of acute ischemic stroke. It provides extended therapeutic time compared to most of the other treatment procedure. Moreover, with the increasing impact of telemedicine and e-prescription and e-medical adherence the acute ischemic stroke diagnosis and treatment market is expected to flourish at a healthy rate during the forecast period.
North America was the largest market of acute ischemic stroke diagnosis and treatment in 2014. The market dominance of the North America is attributed to high percentage of patients suffering from strokes, in admiration with the technical advancement in the treatment procedure acute ischemic stroke in the region. It is then followed by Europe; the large population of baby boomers in Europe is one of the factors for a high market share in acute ischemic stroke diagnosis and treatment market. Country wise, the U.S., Canada are two of the major markets in North America. Germany, Italy, the U.K, and France are some of the dominant market in Europe, Japan, China and India are the major market of Asia Pacific region.
To know more visit: https://www.psmarketresearch.com/market-analysis/acute-ischemic-stroke-diagnosis-and-treatment-market
Some of the leading players operating in global acute ischemic stroke diagnosis and treatment market include, Abbott Laboratories, Covidien plc, Johnson & Johnson (Cordis Corporation), Penumbra, Inc., Philips Healthcare, GE Healthcare, Hitachi, Ltd., Siemens Healthcare, and Stryker Corporation (Concentric Medical, Inc.).
Capsule Endoscopes Market - Global Market Size, Share and Demand, 2023
Global capsule endoscopes market is growing with a significant rate due to demand for faster and accurate diagnostic tools, for managing the rising prevalence of gastrointestinal diseases, colorectal cancer, and government initiatives. Moreover, increasing aging population and introduction of technologically advanced capsules such as Wi-Fi enabled capsule and longer battery life capsule are expected to support the capsule endoscopes market to grow in the coming years. Aging increases the risk of gastrointestinal disorders, such as inflammatory bowel disease, CRC, and appendicitis.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/capsule-endoscopes-market/report-sample
According to the World Health Organization, the population of 60 years and above is expected to rise to 15% in 2050. Peptic ulcers are general in elderly people and are mostly caused due to prolonged usage of H, Pylori infection and non-steroidal anti-inflammatory drugs (NSAIDS). Some of the patients suffering from ulcers have serious complications and sometimes it becomes life threatening for them. This is expected to expand the patient base, resulting in the growth of the capsule endoscopes market. Moreover, the use of hybrid and magnetic capsules to enable enhanced imaging and better control are ongoing research attributes, which is further expected to support the capsule endoscopes market to grow in the coming years.
North America leads the capsule endoscopes market, due to the presence of favorable reimbursement policies, rising prevalence rate of gastrointestinal disorders and colorectal cancer, increasing adoption of minimally invasive capsule endoscopy by patients and advanced healthcare infrastructure in the region. Asia-Pacific is expected to grow with the highest rate in the coming years, due to increasing disposable income, increasing patient awareness levels, presence of untapped opportunities regarding cancer screening and improving healthcare infrastructure.
Explore more about “global capsule endoscopes market” at: https://www.psmarketresearch.com/market-analysis/capsule-endoscopes-market
Healthcare professionals and patients are shifting from conventional methods, such double balloon enteroscopy to the capsule endoscopes. All this is due to benefits from capsule endoscopes such as a real time image of the entire small intestine, quick and easy diagnosis, providing extensive growth to the capsule endoscopes market in the coming years.
Some of the competitors in the capsule endoscopes market are Olympus Corporation, Capso Vision Inc., Chongqing Jinshan Science & Technology Co., RF System lab, Fujifilm Holding Corporation, Given Imaging Ltd., and IntroMedic Co., Ltd.
Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/medical-devices
